FDA Grants Orphan Drug Status to OBI's Targeted Pancreatic Cancer Therapy

Dec 27, 2019

|

NEW YORK – OBI Pharma announced Thursday that the US Food and Drug Administration granted orphan drug designation to its investigational therapy OBI-999 for pancreatic cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

FDA Grants Orphan Drug Status to OBI's Targeted Pancreatic Cancer Therapy

To read the full story....

Breaking News

Elevation Oncology, US Oncology Research Pair Up to Enroll Patients for Seribantumab Trial

Celyad Oncology, Merck Partner to Study CAR T-cell Therapy With Keytruda in Colorectal Cancer

Bayer's ATR Inhibitor May Benefit Cancers With ATM Aberrations, Early Data Suggest

FDA Expands Patient Access to BioMed Valley's ERK Inhibitor

Sema4, Janssen Partner on Patient Identification for Cancer Clinical Trials

Basilea Pharmaceutica to Evaluate FGFR Inhibitor Derazantinib in Gastric Cancer Patients

What's Popular?

Novartis Melanoma Triplet Therapy Failure Raises Questions for Other Combos; Subgroups May Benefit

FDA Expands Patient Access to BioMed Valley's ERK Inhibitor

Relay Therapeutics Uses Protein Motion Simulation to Develop Highly Selective Precision Cancer Drugs

Growing Data on Vitrakvi Demonstrate Enduring Activity Across Variety of NTRK-Positive Tumor Types

Celyad Oncology, Merck Partner to Study CAR T-cell Therapy With Keytruda in Colorectal Cancer

Sponsorships